

Giuseppe Viale

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8082564/giuseppe-viale-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

446 papers	45,726 citations	91 h-index	207 g-index
464 ext. papers	54,327 ext. citations	6.9 avg, IF	6.78 L-index

#	Paper	IF	Citations
446	Evolution of low HER2 expression between early and advanced-stage breast cancer.. <i>European Journal of Cancer</i> , 2022 , 163, 35-43	7.5	5
445	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.. <i>Npj Breast Cancer</i> , 2022 , 8, 1	7.8	0
444	Abstract OT2-26-01: Open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC). <i>DESTINY Breast 12 - European Society for Medical Oncology</i> , 2022 , 63, OT2-26-01-OT2-26-01	10.1	
443	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.. <i>European Journal of Cancer</i> , 2022 , 164, 52-61	7.5	
442	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.. <i>Frontiers in Molecular Biosciences</i> , 2022 , 9, 834651	5.6	7
441	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 172, 103643	7	5
440	Pathology after neoadjuvant treatment - How to assess residual disease. <i>Breast</i> , 2021 ,	3.6	2
439	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021 , 7, 150	7.8	17
438	Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2021 , 1	4.4	
437	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. <i>European Journal of Cancer</i> , 2021 , 145, 197-209	7.5	3
436	Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. <i>British Journal of Cancer</i> , 2021 , 125, 38-47	8.7	1
435	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , 2021 , 22, 476-488	21.7	47
434	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 67	7.8	1
433	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1448-1457	2.2	50
432	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021 , 27, 4311-4324	12.9	5
431	ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 555-555	2.2	0
430	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. <i>Cancer Discovery</i> , 2021 , 11, 2474-2487	24.4	17

429	Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. <i>Cancer Cell</i> , 2021 , 39, 708-724.e11	24.3	34
428	ALEXANDRA/Impassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS597-TPS597	2.2	1
427	Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. <i>Lancet Oncology</i> , 2021 , 22, 597-608	21.7	31
426	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	21
425	Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021 , 384, 2394-2405	59.2	145
424	Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review. <i>Cancers</i> , 2021 , 13,	6.6	1
423	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021 , 11, 2796-2811	24.4	10
422	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 504-512	12.9	3
421	Metaplastic breast cancer: Prognostic and therapeutic considerations. <i>Journal of Surgical Oncology</i> , 2021 , 123, 61-70	2.8	14
420	Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 804-812	3.6	38
419	Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 644737	5.3	18
418	Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. <i>Frontiers in Oncology</i> , 2021 , 11, 723693	5.3	0
417	Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review. <i>Current Oncology</i> , 2021 , 28, 3384-3392	2.8	1
416	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , 2021 , 22, 1139-1150	21.7	24
415	CLRM-14. OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS (BM) WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HUMAN EPIDERMAL GROWTH FACTOR	0.9	
414	RECEPTOR 2-POSITIVE BREAST CANCER (HER2+ BC). DESTINY-BREAST12. Neuro-Oncology Advances, 2021, 3, IV4-IV4 A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 265-275	4.4	6
413	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. <i>Breast</i> , 2021 , 59, 94-101	3.6	3
412	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021 , 32, 1216-1235	10.3	44

411	Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2499-2505	3.6	1
410	Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.. <i>BMJ, The</i> , 2021 , 375, e066381	5.9	4
409	Pegylated Liposomal Doxorubicin (Caelyx) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial.. <i>Current Oncology</i> , 2021 , 28, 5167-5178	2.8	1
408	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020 , 6, 16	7.8	47
407	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 17	7.8	54
406	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020 , 250, 667-684	9.4	83
405	Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2883-2891	2.2	18
404	Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1186-1197	2.2	5
403	Post-radiotherapy vascular lesions of the breast: immunohistochemical and molecular features of 74 cases with long-term follow-up and literature review. <i>Histopathology</i> , 2020 , 77, 293-302	7.3	4
402	Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101963	14.4	28
401	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1346-1366	2.2	249
400	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2020 , 144, 545-563	5	82
399	Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast. <i>Modern Pathology</i> , 2020 , 33, 1065-1077	9.8	0
398	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1951-1962	2.2	74
397	MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 506-506	2.2	29
396	Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 555-555	2.2	2
395	Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1020-1020	2.2	2
394	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e12570-e12570	2.2	

393	Integration of the stem cell biology-based genomic tool, StemPrintER, with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2- breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1057-1057	2.2	
392	Expression of tumor-associated antigens in breast cancer subtypes. <i>Breast</i> , 2020 , 49, 202-209	3.6	5
391	Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses. <i>Breast Cancer Research</i> , 2020 , 22, 107	8.3	16
390	Correlation of size and focality with prognosis in small breast carcinoma: a single institution case series. <i>Breast</i> , 2020 , 54, 164-169	3.6	0
389	Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy. <i>Breast</i> , 2020 , 53, 138-142	3.6	4
388	A role for the immune system in advanced laryngeal cancer. <i>Scientific Reports</i> , 2020 , 10, 18327	4.9	6
387	A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. <i>Genome Medicine</i> , 2020 , 12, 94	14.4	6
386	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1293-1303	2.2	45
385	Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). <i>BMC Cancer</i> , 2019 , 19, 903	4.8	7
384	Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz051	4.6	1
383	Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series. <i>Radiotherapy and Oncology</i> , 2019 , 133, 68-76	5.3	3
382	Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	5
381	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 103-114	4.4	17
380	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 557-568	4.4	5
379	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. <i>Histopathology</i> , 2019 , 75, 225-235	7.3	37
378	Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study. <i>EBioMedicine</i> , 2019 , 42, 352-362	8.8	22
377	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 386-395	2.2	11
376	Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. <i>Breast Cancer Research</i> , 2019 , 21, 30	8.3	37

375	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	4.0	137
374	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 371-382	21.7	200
373	Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 451-458	4.4	14
372	Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1012-1012	2.2	21
371	HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 502-502	2.2	41
370	Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 527-527	2.2	2
369	ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS598 ^{2,2} -TPS598 ^{2,2}		
368	BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5572-5572	2.2	
367	The developmental origins of high grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e17063-e17063	2.2	
366	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. <i>Breast Cancer Research</i> , 2019 , 21, 153	8.3	7
365	Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease. <i>Breast</i> , 2019 , 48 Suppl 1, S49-S52	3.6	2
364	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , 2019 , 24, 165-171	5.7	13
363	OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. <i>Liver International</i> , 2019 , 39, 158-167	7.9	19
362	Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. <i>Lancet Oncol</i> 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC	10.2	5
361	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 768-776	9.7	55
360	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2018 , 19, 249-256	21.7	89
359	Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer. <i>Journal of Controlled Release</i> , 2018 , 280, 76-86	11.7	33
358	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018 , 24, 3079-3086	12.9	9

357	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2018 , 170, 351-360	4.4	5
356	The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. <i>Journal of Clinical Pathology</i> , 2018 , 71, 767-773	3.9	7
355	HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018 , 26, 239-245	1.9	18
354	Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes. <i>Clinical Breast Cancer</i> , 2018 , 18, e401-e405	3	10
353	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018 , 52, 16-25	12.7	181
352	Endomyocardial biopsy guided by intracardiac echocardiography as a key step in intracardiac mass diagnosis. <i>BMC Cardiovascular Disorders</i> , 2018 , 18, 15	2.3	13
351	Sex as a predictor of response to cancer immunotherapy - Authors' reply. <i>Lancet Oncology, The</i> , 2018 , 19, e380-e381	21.7	4
350	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 1335-1343	13.4	24
349	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. <i>International Journal of Oncology</i> , 2018 , 52, 424-432	4.4	5
348	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 503-503	2.2	11
347	Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the BOOLE trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 517-517	2.2	1
346	Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 521-521	2.2	5
345	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , 2018 , 19, 27-39	21.7	413
344	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 127-138	21.7	62
343	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1941-1948	2.2	73
342	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2105-2122	2.2	646
341	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1385-1393	21.7	195
340	The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 1190-1200	6.7	10

339	The Lymph Node and the Metastasis. <i>New England Journal of Medicine</i> , 2018 , 378, 2045-2046	59.2	15
338	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 1364-1382	5	295
337	Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. <i>Lancet Oncology, The</i> , 2018 , 19, 737-746	21.7	353
336	An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers. <i>Clinical Cancer Research</i> , 2017 , 23, 62-72	12.9	19
335	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER α metastatic breast cancer. <i>Nature Genetics</i> , 2017 , 49, 444-450	36.3	46
334	Comparison of Treatment Outcome Between Invasive Lobular and Ductal Carcinomas in Patients Receiving Partial Breast Irradiation With Intraoperative Electrons. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 173-181	4	10
333	Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers. <i>EMBO Molecular Medicine</i> , 2017 , 9, 655-671	12	28
332	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2F scaffolding Function. <i>Cancer Cell</i> , 2017 , 32, 444-459.e7	24.3	44
331	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3867-3876	2.2	263
330	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma	5.1	299
329	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in</i>	5.1	293
328	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper \square . <i>Breast Cancer Research</i> , 2017 , 19, 55	8.3	20
327	The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group. <i>Npj Breast Cancer</i> , 2017 , 3, 23	7.8	5
326	Controversies in treatment selection for patients with equivocal ER and HER2 results. <i>Breast</i> , 2017 , 34 Suppl 1, S61-S63	3.6	1
325	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2017 , 377, 122-131	59.2	688
324	Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. <i>Breast</i> , 2017 , 31, 51-56	3.6	78
323	From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. <i>Breast</i> , 2017 , 31, 241-243	3.6	1
322	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	7

321	TCTN2: a novel tumor marker with oncogenic properties. <i>Oncotarget</i> , 2017 , 8, 95256-95269	3.3	4
320	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 717-29	59.2	969
319	Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. <i>Breast Cancer Research</i> , 2016 , 18, 110	8.3	15
318	Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. <i>Breast</i> , 2016 , 30, 151-155	3.6	23
317	RAB2A controls MT1-MMP endocytic and E-cadherin polarized Golgi trafficking to promote invasive breast cancer programs. <i>EMBO Reports</i> , 2016 , 17, 1061-80	6.5	48
316	A Trust-Based Pact in Research Biobanks. From Theory to Practice. <i>Bioethics</i> , 2016 , 30, 260-71	2	13
315	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3400-8	2.2	56
314	FAT1: a potential target for monoclonal antibody therapy in colon cancer. <i>British Journal of Cancer</i> , 2016 , 115, 40-51	8.7	16
313	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. <i>JAMA Oncology</i> , 2016 , 2, 217-24	13.4	19
312	Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 463-9	4.4	19
311	Genomic Characterization of Primary Invasive Lobular Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1872-81	2.2	175
310	Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2016 , 7, 37160-37176	3.3	5
309	ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer. <i>Oncotarget</i> , 2016 , 7, 63596-63610	3.3	13
308	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 323-31	4.4	73
307	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016 , 29, 1155-64	9.8	154
306	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2221-31	2.2	112
305	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. <i>JAMA Oncology</i> , 2016 , 2, 1040-7	13.4	48
304	HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. <i>Anticancer Research</i> , 2016 , 36, 3537-40	2.3	1

303	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. <i>Modern Pathology</i> , 2015 , 28, 1185-201	9.8	144
302	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2772-9	2.2	91
301	Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment. <i>Acta Oncologica</i> , 2015 , 54, 1040-8	3.2	21
300	Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. <i>Breast</i> , 2015 , 24, 263-71	3.6	11
299	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. <i>Breast</i> , 2015 , 24, 290-3	3.6	18
298	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015 , 26, 1533-46	10.3	1122
297	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015 , 28, 778-86	9.8	168
296	CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2015 , 151, 373-84	4.4	24
295	Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015 , 15, 259-65	3	29
294	Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data. <i>Modern Pathology</i> , 2015 , 28, 1528-34	9.8	37
293	Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 629-34	1.9	58
292	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 275-86	4.4	30
291	Reply to E.A. Rakha et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1302-4	2.2	24
290	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015 , 28, 1481-91	9.8	144
289	Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial. <i>Cancer Prevention Research</i> , 2015 , 8, 888-94	3.2	20
288	Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 136, 413-22	11.5	75
287	A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response. <i>Breast</i> , 2015 , 24 Suppl 2, S23-5	3.6	2
286	ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 543-55	4.4	11

285	Adjuvant ovarian suppression in premenopausal breast cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 436-46	59.2	462
284	Core needle biopsy as a front line diagnostic approach for lymphoma patients. <i>Hematological Oncology</i> , 2015 , 33, 247-9	1.3	6
283	Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. <i>Antioxidants and Redox Signaling</i> , 2015 , 23, 15-29	8.4	11
282	Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study. <i>Clinical Breast Cancer</i> , 2015 , 15, e257-62	3	1
281	A gut-vascular barrier controls the systemic dissemination of bacteria. <i>Science</i> , 2015 , 350, 830-4	33.3	269
280	Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience. <i>Clinical Breast Cancer</i> , 2015 , 15, 440-7	3	1
279	Mining cancer gene expression databases for latent information on intronic microRNAs. <i>Molecular Oncology</i> , 2015 , 9, 473-87	7.9	4
278	Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1002-1002	2.2	5
277	OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS1109-TPS1109	2.2	11
276	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014 , 23, 69-75	3.6	72
275	Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. <i>Clinical Breast Cancer</i> , 2014 , 14, 258-64	3	31
274	Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. <i>Breast</i> , 2014 , 23, 44-9	3.6	20
273	Outcomes of patients with breast cancer who present with ipsilateral supraclavicular or internal mammary lymph node metastases. <i>Clinical Breast Cancer</i> , 2014 , 14, 53-60	3	21
272	Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 485-92	4.4	52
271	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. <i>European Journal of Cancer</i> , 2014 , 50, 277-89	7.5	163
270	Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 327-35	4.4	17
269	Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2794-803	2.2	197
268	A RAB5/RAB4 recycling circuitry induces a proteolytic invasive program and promotes tumor dissemination. <i>Journal of Cell Biology</i> , 2014 , 206, 307-28	7.3	90

267	Angiopoietin-like 7, a novel pro-angiogenetic factor over-expressed in cancer. <i>Angiogenesis</i> , 2014 , 17, 881-96	10.6	40
266	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , 2014 , 21, 545-54	5.7	48
265	Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 146, 573-82	4.4	8
264	Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 107-18	59.2	500
263	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. <i>Modern Pathology</i> , 2014 , 27, 4-18	9.8	191
262	Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method. <i>Oncologist</i> , 2014 , 19, 1118-26	5.7	30
261	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. <i>Archives of Pathology and Laboratory Medicine</i> , 2014 , 138, 241-56	5	738
260	Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence. <i>Breast</i> , 2014 , 23, 829-35	3.6	7
259	Prevalence and clinicopathologic correlates of O ⁶ -methylguanine-DNA methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs. <i>Clinical Breast Cancer</i> , 2014 , 14, 285-90	3	8
258	Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies. <i>Molecular Oncology</i> , 2014 , 8, 221-31	7.9	24
257	Reply to letter by Ieni et al. <i>European Journal of Cancer</i> , 2014 , 50, 1038-9	7.5	
256	Outcome of male breast cancer: a matched single-institution series. <i>Clinical Breast Cancer</i> , 2014 , 14, 371-3	3.7	26
255	First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA11-LBA14	2.2	26
254	First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA4-LBA7	2.2	35
253	Atypical primary pulmonary meningioma: a report of a case suspected of being a lung metastasis. <i>Ecancermedicalscience</i> , 2014 , 8, 414	2.7	8
252	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , 2013 , 14, 297-305	21.7	775
251	The clinical relevance of micropapillary carcinoma of the breast: a case-control study. <i>Histopathology</i> , 2013 , 63, 217-24	7.3	42
250	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013 , 24, 2206-23	10.3	2048

249	An international Ki67 reproducibility study. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1897-906	9.7	398
248	Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88, 427-36	7	114
247	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. <i>Journal of Clinical Oncology</i> , 2013 , 31, 860-7	2.2	1023
246	Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. <i>Lancet Oncology, The</i> , 2013 , 14, 1269-77	21.7	535
245	Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1332-4	9.7	31
244	Therapeutic effect of β blockers in triple-negative breast cancer postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 567-75	4.4	85
243	Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. <i>Archives of Gynecology and Obstetrics</i> , 2013 , 288, 1203-12	2.5	8
242	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3997-4013	2.2	2593
241	Characterization and clinical impact of residual disease after neoadjuvant chemotherapy. <i>Breast</i> , 2013 , 22 Suppl 2, S88-91	3.6	11
240	Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. <i>Breast</i> , 2013 , 22, 200-202	3.6	17
239	Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"? <i>Breast</i> , 2013 , 22, 1046-51	3.6	23
238	Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. <i>Clinical Breast Cancer</i> , 2013 , 13, 31-9	3	99
237	Immunohistochemically defined subtypes and outcome of apocrine breast cancer. <i>Clinical Breast Cancer</i> , 2013 , 13, 95-102	3	42
236	Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 157-65	4.4	32
235	Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 303-10	4.4	6
234	Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1954-60	2.2	28
233	A case of NUT midline carcinoma with no HPV infection, slight EWSR1 rearrangement and strong expression of EGFR. <i>Tumori</i> , 2013 , 99, e152-e155	1.7	3
232	Prognostic effect of beta blockers (BB) in triple-negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1061-1061	2.2	2

231	Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 529-529	2.2	3
230	Locked-in syndrome after basiliary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient. <i>Ecancermedicalscience</i> , 2013 , 7, 382	2.7	3
229	Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 617-617	2.2	
228	Biopsy of liver metastasis for women with breast cancer: impact on survival. <i>Breast</i> , 2012 , 21, 284-8	3.6	18
227	Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. <i>Cancer</i> , 2012 , 118, 17-26	6.4	49
226	Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 819-25	4.4	54
225	CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 441-51	9.7	273
224	Ovarian serous papillary carcinoma, metastatic to intramammary lymph-node mimic a primary breast carcinoma on RX mammography. <i>Breast Journal</i> , 2012 , 18, 484-5	1.2	5
223	Dissecting the heterogeneity of triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1879-87	2.2	304
222	A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. <i>Breast</i> , 2012 , 21, 621-8	3.6	2
221	Identification of new hematopoietic cell subsets with a polyclonal antibody library specific for neglected proteins. <i>PLoS ONE</i> , 2012 , 7, e34395	3.7	1
220	Primary and secondary angiosarcomas of the breast: a single institution experience. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 1081-8	4.4	41
219	Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 131-7	4.4	30
218	Invasive lobular breast cancer: subtypes and outcome. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 713-23	4.4	94
217	Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. <i>Clinical Breast Cancer</i> , 2012 , 12, 207-14	3	52
216	The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study. <i>Acta Oncologica</i> , 2012 , 51, 653-61	3.2	51
215	HER2 testing in gastric cancer: a practical approach. <i>Modern Pathology</i> , 2012 , 25, 637-50	9.8	386
214	Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. <i>Gut</i> , 2012 , 61, 1007-15	19.2	209

213	Comparison of molecular (BluePrint and MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 32-32	2.2	1
212	How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. <i>PLoS ONE</i> , 2012 , 7, e37379	3.7	150
211	Merkel cell polyomavirus in gastrointestinal neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4120-4120	2.2	
210	Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1022-1022	2.2	
209	Intrinsic subtype and its clinical significance in early node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 504-504	2.2	
208	Pirin inhibits cellular senescence in melanocytic cells. <i>American Journal of Pathology</i> , 2011 , 178, 2397-406	5.8	25
207	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. <i>Lancet Oncology, The</i> , 2011 , 12, 1162-8	21.7	15
206	An atlas of altered expression of deubiquitinating enzymes in human cancer. <i>PLoS ONE</i> , 2011 , 6, e15891	3.7	78
205	Influence of margin status on outcomes in lobular carcinoma: experience of the European Institute of Oncology. <i>Annals of Surgery</i> , 2011 , 253, 580-4	7.8	14
204	Immunohistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1039-49	8.9	54
203	Pathological work up of the primary tumor: getting the proper information out of it. <i>Breast</i> , 2011 , 20 Suppl 3, S82-6	3.6	19
202	Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. <i>Breast</i> , 2011 , 20, 34-8	3.6	7
201	Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. <i>Breast</i> , 2011 , 20, 319-23	3.6	36
200	Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institution. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2879-84	3.1	19
199	Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 431-44	4.4	25
198	Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 867-75	4.4	40
197	Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011 , 458, 497-503	5.1	6
196	The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. <i>EMBO Molecular Medicine</i> , 2011 , 3, 480-94	12	58

195	Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1656-64	9.7	1156
194	Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. <i>Cancer Prevention Research</i> , 2011 , 4, 1181-9	3.2	50
193	Intravascular papillary endothelial hyperplasia of the renal vein. <i>International Journal of Surgical Pathology</i> , 2011 , 19, 518-20	1.2	7
192	Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2966-73	2.2	107
191	Review article: pulmonary sarcomatoid carcinomas: a practical overview. <i>International Journal of Surgical Pathology</i> , 2010 , 18, 103-20	1.2	117
190	Aggressive treatment approach for cloacogenic carcinoma of the anorectum: report from a single cancer center. <i>Digestive Surgery</i> , 2010 , 27, 297-301	2.5	7
189	Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. <i>Oncologist</i> , 2010 , 15, 1164-8	5.7	133
188	Reply to V. Arena et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e61-e61	2.2	3
187	American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2784-95	2.2	2145
186	Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 21535-40	11.5	50
185	Reply to D. Crivellari et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e258-e259	2.2	2
184	Nonpalpable breast carcinomas: long-term evaluation of 1,258 cases. <i>Oncologist</i> , 2010 , 15, 1248-52	5.7	21
183	Underuse of anthracyclines in women with HER-2+ advanced breast cancer. <i>Oncologist</i> , 2010 , 15, 665-72	5.7	8
182	Axillary lymph node involvement in women with breast cancer: does it depend on age?. <i>Clinical Breast Cancer</i> , 2010 , 10, 318-21	3	10
181	Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. <i>Cell</i> , 2010 , 140, 62-73	56.2	719
180	The classification of lung carcinoma: time to change the morphology-based approach?. <i>International Journal of Surgical Pathology</i> , 2010 , 18, 161-72	1.2	19
179	Triple-negative breast cancer: disease entity or title of convenience?. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 683-92	19.4	588
178	Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. <i>Annals of Surgery</i> , 2010 , 251, 595-600	7.8	373

177	Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2010 , 121, 211-8	4.4	31
176	Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 607-17	4.4	150
175	Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 689-99	4.4	55
174	Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. <i>Clinical Breast Cancer</i> , 2010 , 10, 483-8	3	17
173	Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer. <i>Breast</i> , 2010 , 19, 128-32	3.6	5
172	Management of triple negative breast cancer. <i>Breast</i> , 2010 , 19, 312-21	3.6	148
171	Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. <i>Anticancer Research</i> , 2010 , 30, 4269-81	2.3	28
170	Alterations of the Notch pathway in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 22293-8	11.5	307
169	Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5693-9	2.2	203
168	Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1735-6; author reply 1736-7	9.7	4
167	Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years. <i>Oncologist</i> , 2009 , 14, 201-12	5.7	18
166	Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2962-9	2.2	141
165	Ultrasound-guided vacuum assisted breast biopsy in the assessment of C3 breast lesions by ultrasound-guided fine needle aspiration cytology: results and costs in comparison with surgery. <i>Breast</i> , 2009 , 18, 73-7	3.6	12
164	Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment. <i>Breast</i> , 2009 , 18 Suppl 3, S32-6	3.6	8
163	Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 211-4	4.4	37
162	The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 295-302	4.4	222
161	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 317-28	4.4	150
160	Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 359-69	4.4	74

159	The surgical margin status after breast-conserving surgery: discussion of an open issue. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 397-402	4.4	75
158	Conservative surgery in patients with multifocal/multicentric breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 577-83	4.4	68
157	Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. <i>Journal of Pathology</i> , 2009 , 219, 1-2	9.4	46
156	Systemic therapy as a first choice treatment for idiopathic granulomatous mastitis. <i>Journal of Cutaneous Pathology</i> , 2009 , 36, 689-91	1.7	33
155	Rethinking TNM: a breast cancer classification to guide to treatment and facilitate research. <i>Breast Journal</i> , 2009 , 15, 291-5	1.2	42
154	Pathological definition of triple negative breast cancer. <i>European Journal of Cancer</i> , 2009 , 45 Suppl 1, 5-10	7.5	20
153	Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. <i>Anti-Cancer Drugs</i> , 2009 , 20, 197-203	2.4	17
152	Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. <i>Hepato-Gastroenterology</i> , 2009 , 56, 829-34		13
151	Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer. <i>Anticancer Research</i> , 2009 , 29, 5111-9	2.3	12
150	NUMB controls p53 tumour suppressor activity. <i>Nature</i> , 2008 , 451, 76-80	50.4	298
149	Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. <i>Clinical Breast Cancer</i> , 2008 , 8, 436-42	3	21
148	Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. <i>Breast</i> , 2008 , 17, 506-11	3.6	27
147	Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. <i>Breast</i> , 2008 , 17, 654-60	3.6	8
146	Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature. <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 513-21	4.4	85
145	Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. <i>Lancet Oncology, The</i> , 2008 , 9, 23-8	21.7	131
144	Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 207-12	9.7	183
143	Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1404-10	2.2	84
142	Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5569-75	2.2	262

141	The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. <i>Cancer Research</i> , 2008 , 68, 1110-8	10.1	69
140	Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. <i>Journal of Clinical Oncology</i> , 2008 , 26, 258-63	2.2	78
139	Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. <i>Annals of Surgery</i> , 2008 , 247, 136-42	7.8	83
138	Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. <i>Annals of Surgery</i> , 2008 , 247, 315-9	7.8	104
137	Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 965-71	3.5	18
136	Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 667-72	3.5	74
135	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. <i>Leukemia Research</i> , 2008 , 32, 1628-32	2.7	1
134	Fluorescent in situ hybridization as a screening test for HER2 amplification in G2 and G3 breast cancers of lobular and ductal histotype and metastases. <i>Oncology Reports</i> , 2008 , 19, 1271-5	3.5	2
133	Effectiveness of LigaSure diathermy coagulation in liver surgery. <i>Surgical Technology International</i> , 2008 , 17, 33-8	0.8	12
132	Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. <i>Modern Pathology</i> , 2007 , 20, 843-55	9.8	87
131	Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. <i>Breast</i> , 2007 , 16, 73-80	3.6	14
130	The evolution of the conservative approach to breast cancer. <i>Breast</i> , 2007 , 16, 120-9	3.6	30
129	Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. <i>Breast</i> , 2007 , 16, 262-70	3.6	10
128	The sentinel node biopsy under local anesthesia in breast cancer: advantages and problems, how the technique influenced the activity of a breast surgery department; update from the European Institute of Oncology with more than 1000 cases. <i>Breast</i> , 2007 , 16, 527-32	3.6	11
127	Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. <i>Breast Cancer Research and Treatment</i> , 2007 , 101, 349-53	4.4	165
126	Ultrasound-guided vacuum-assisted core breast biopsy: experience with 406 cases. <i>Breast Cancer Research and Treatment</i> , 2007 , 102, 103-10	4.4	80
125	Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. <i>Breast Cancer Research and Treatment</i> , 2007 , 105, 81-5	4.4	40
124	Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 727-37	9.7	187

123	Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3846-52	2.2	340
122	3q26 Amplification and polysomy of chromosome 3 in squamous cell lesions of the lung: a fluorescence in situ hybridization study. <i>Clinical Cancer Research</i> , 2007 , 13, 1995-2004	12.9	27
121	Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. <i>Clinical Cancer Research</i> , 2007 , 13, 3207-14	12.9	759
120	The Ligasure vessel sealer in liver resection: a pilot study. <i>Hepato-Gastroenterology</i> , 2007 , 54, 2353-7		4
119	Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. <i>Breast</i> , 2006 , 15, 3-8	3.6	47
118	A primary pure yolk sac tumor of the lung exhibiting CDX-2 immunoreactivity and increased serum levels of alkaline phosphatase intestinal isoenzyme. <i>International Journal of Surgical Pathology</i> , 2006 , 14, 247-51	1.2	27
117	Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1183-92	9.7	976
116	Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1571-81	9.7	129
115	Frequent alterations in the expression of serine/threonine kinases in human cancers. <i>Cancer Research</i> , 2006 , 66, 8147-54	10.1	121
114	Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. <i>Lancet Oncology</i> , 2006 , 7, 983-90	21.7	349
113	Salivary gland-type tumors with myoepithelial differentiation arising in pulmonary hamartoma: report of 2 cases of a hitherto unrecognized association. <i>American Journal of Surgical Pathology</i> , 2006 , 30, 375-87	6.7	18
112	The rete mirabile of the cranial base: a millenary legend. <i>Neurosurgery</i> , 2006 , 58, 1198-208; discussion 1198-208	3.2	9
111	Further Axillary Metastases Associated With Isolated Tumor Cells in Sentinel Lymph Nodes of Breast Cancer Patients. <i>Annals of Surgery</i> , 2006 , 243, 287	7.8	
110	Immunoreactivity for sex steroid hormone receptors in pulmonary hamartomas. <i>American Journal of Surgical Pathology</i> , 2006 , 30, 819-27	6.7	9
109	A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2006 , 17, 1201-9	2.4	11
108	Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA. <i>Breast Cancer Research and Treatment</i> , 2006 , 98, 185-90	4.4	16
107	Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 448, 7-15	5.1	16
106	Pathologic examination of the axillary sentinel lymph nodes in patients with early-stage breast carcinoma: current and resolving controversies on the basis of the European Institute of Oncology experience. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 448, 211-7	5.1	26

105	Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 448, 442-8	5.1	24
104	Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 468-77	8.9	3
103	Prediction of cancer outcome with microarrays. <i>Lancet, The</i> , 2005 , 365, 1685-6; author reply 1686	4.0	4
102	Branchiogenic carcinoma--conceptual or true clinico-pathological entity?. <i>Cancer Treatment Reviews</i> , 2005 , 31, 106-14	14.4	20
101	Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. <i>American Journal of Surgical Pathology</i> , 2005 , 29, 179-87	6.7	193
100	Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. <i>Annals of Surgery</i> , 2005 , 241, 319-25	7.8	187
99	Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy. <i>Annals of Surgical Oncology</i> , 2005 , 12, 895-9	3.1	61
98	Pulsed dose-rate perioperative interstitial brachytherapy for soft tissue sarcomas of the extremities and skeletal muscles of the trunk. <i>Annals of Surgical Oncology</i> , 2005 , 12, 935-42	3.1	17
97	Accuracy of computed tomography and magnetic resonance imaging in the detection of lymph node involvement in cervix carcinoma. <i>European Radiology</i> , 2005 , 15, 2469-74	8	52
96	Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. <i>Nature Immunology</i> , 2005 , 6, 507-14	19.1	647
95	Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. <i>Modern Pathology</i> , 2005 , 18, 1277-82	9.8	71
94	Histopathology of primary breast cancer 2005. <i>Breast</i> , 2005 , 14, 487-92	3.6	15
93	Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. <i>International Journal of Cancer</i> , 2005 , 113, 101-8	7.5	28
92	Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. <i>Cancer</i> , 2005 , 103, 492-500	6.4	156
91	A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005 , 447, 969-77	5.1	14
90	Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005 , 446, 604-12	5.1	10
89	The sentinel lymph node biopsy under local anesthesia in breast carcinoma: experience of the European Institute of Oncology and impact on quality of life. <i>Breast Cancer Research and Treatment</i> , 2005 , 89, 69-74	4.4	14
88	Breast hamartoma: a case report. <i>Breast Cancer Research and Treatment</i> , 2005 , 89, 145-7	4.4	9

87	The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology. <i>Breast Cancer Research and Treatment</i> , 2005 , 89, 159-63	4.4	77
86	Conservative treatment of breast cancer: its evolution. <i>Breast Cancer Research and Treatment</i> , 2005 , 94, 195-8	4.4	26
85	Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1379-89	2.2	135
84	Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 242-8	12.9	18
83	Surgical treatment of advanced colorectal cancer in the elderly. <i>Chirurgia Italiana</i> , 2005 , 57, 589-96		5
82	Adenomyoepithelioma of the Breast, Presenting as a Cancer. <i>Tumori</i> , 2004 , 90, 337-339	1.7	5
81	Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. <i>Clinical Cancer Research</i> , 2004 , 10, 6622-8	12.9	293
80	An alternative viewpoint. <i>International Journal of Surgical Pathology</i> , 2004 , 12, 307-9	1.2	1
79	Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4966-70	2.2	30
78	Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. <i>EMBO Journal</i> , 2004 , 23, 1144-54	13	98
77	K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. <i>Modern Pathology</i> , 2004 , 17, 538-46	9.8	44
76	CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients. <i>Modern Pathology</i> , 2004 , 17, 711-21	9.8	39
75	Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. <i>Modern Pathology</i> , 2004 , 17, 1513-20	9.8	16
74	CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004 , 445, 449-55	5.1	47
73	Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. <i>Cancer</i> , 2004 , 101, 905-12	6.4	48
72	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. <i>International Journal of Cancer</i> , 2004 , 112, 71-7	7.5	15
71	Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients. <i>Journal of Surgical Oncology</i> , 2004 , 85, 123-8	2.8	26
70	Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. <i>Journal of Cell Biology</i> , 2004 , 167, 215-21	7.3	401

69	An intriguing fragment of pre-hippocratic medicine in Aeschylus. <i>Neurosurgery</i> , 2004 , 55, 761-5; discussion 765-6	3.2	
68	Sentinel node biopsy in male breast cancer. <i>Nuclear Medicine Communications</i> , 2004 , 25, 139-43	1.6	46
67	Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. <i>Anticancer Research</i> , 2004 , 24, 1261-6	2.3	23
66	A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 779-90	9.7	168
65	Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. <i>American Journal of Surgical Pathology</i> , 2003 , 27, 1203-15	6.7	79
64	Ectopic breast tissue as a possible cause of false-positive axillary sentinel lymph node biopsies. <i>American Journal of Surgical Pathology</i> , 2003 , 27, 513-8	6.7	74
63	Cytological features of calcifying epithelial odontogenic tumor (Pindborg tumor) with abundant cementum-like material. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003 , 442, 107-10	5.1	9
62	CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003 , 443, 782-6	5.1	65
61	Basaloid cell carcinoma of the prostate. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003 , 443, 787-91	5.1	26
60	Histopathology of primary breast cancer 2003. <i>Breast</i> , 2003 , 12, 391-6	3.6	8
59	Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. <i>International Journal of Cancer</i> , 2003 , 106, 288-91	7.5	22
58	Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. <i>British Journal of Haematology</i> , 2003 , 120, 695-8	4.5	15
57	Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. <i>Modern Pathology</i> , 2003 , 16, 886-92	9.8	19
56	Identification of a novel KRIT1 mutation in an Italian family with cerebral cavernous malformation by the protein truncation test. <i>Journal of the Neurological Sciences</i> , 2003 , 212, 75-8	3.2	19
55	Sentinel lymph node metastasis in microinvasive breast cancer. <i>Annals of Surgical Oncology</i> , 2003 , 10, 1160-5	3.1	73
54	A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 546-53	59.2	1624
53	Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. <i>Annals of Surgical Oncology</i> , 2002 , 9, 266-71	3.1	41
52	Progesterone receptor immunoreactivity in minute meningothelioid nodules of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 440, 543-6	5.1	22

51	Follicular dendritic cell sarcoma of the breast. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 441, 194-9	5.1	21
50	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. <i>British Journal of Haematology</i> , 2002 , 118, 817-20	4.5	75
49	p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. <i>Laboratory Investigation</i> , 2002 , 82, 1327-34	5.9	38
48	Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users 2002 , 9, 266		2
47	Extensive frozen section examination of axillary sentinel nodes to determine selective axillary dissection. <i>World Journal of Surgery</i> , 2001 , 25, 806-8	3.3	56
46	The problem of the accuracy of intraoperative examination of axillary sentinel nodes in breast cancer. <i>Annals of Surgical Oncology</i> , 2001 , 8, 817-20	3.1	43
45	Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. <i>Cancer</i> , 2001 , 92, 1378-84	6.4	196
44	Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. <i>International Journal of Cancer</i> , 2001 , 92, 666-70	7.5	24
43	Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. <i>International Journal of Cancer</i> , 2001 , 95, 307-12	7.5	64
42	Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2001 , 94, 599-604	7.5	19
41	Clear cell odontogenic carcinoma. Report of two cases and review of the literature. <i>American Journal of Clinical Pathology</i> , 2001 , 116, 107-14	1.9	36
40	Pulmonary epithelial-myoepithelial tumor of unproven malignant potential: report of a case and review of the literature. <i>Modern Pathology</i> , 2001 , 14, 521-6	9.8	58
39	p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. <i>American Journal of Surgical Pathology</i> , 2001 , 25, 1054-60	6.7	310
38	Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. <i>American Journal of Surgical Pathology</i> , 2001 , 25, 363-72	6.7	161
37	The Problem of the Accuracy of Intraoperative Examination of Axillary Sentinel Nodes in Breast Cancer 2001 , 8, 817		4
36	Cellular heterogeneity of granular cell tumours: a clue to their nature?. <i>Journal of Oral Pathology and Medicine</i> , 2000 , 29, 284-90	3.3	13
35	CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000 , 437, 270-4	5.1	39
34	Down-regulation of beta(1C) integrin in breast carcinomas correlates with high proliferative fraction, high histological grade, and larger size. <i>American Journal of Pathology</i> , 2000 , 156, 169-74	5.8	27

33	Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients 1999 , 85, 2433-2438	204
32	Insulin-like growth factor-I expression in normal and diseased endometrium. <i>International Journal of Cancer</i> , 1999 , 80, 188-93	7.5 15
31	p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations. <i>Journal of Pathology</i> , 1999 , 187, 302-7	9.4 38
30	Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. <i>American Journal of Pathology</i> , 1999 , 154, 1345-52	5.8 97
29	Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa. <i>Journal of Pathology</i> , 1998 , 185, 167-74	9.4 35
28	Sentinel-Node Biopsy to Avoid Axillary Dissection in Breast Cancer with Clinically Negative Lymph-Nodes. <i>Breast Journal</i> , 1998 , 4, 63-63	1.2 1
27	Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. <i>Acta Cytologica</i> , 1997 , 41, 1757-61	3 86
26	Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. <i>Lancet, The</i> , 1997 , 349, 1864-7	40 1643
25	Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of in situ end labelling (TUNEL). <i>Journal of Pathology</i> , 1997 , 181, 323-9	9.4 47
24	p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. <i>Cancer</i> , 1997 , 79, 425-32	6.4 128
23	Positive identification in situ of mRNA expression of IL-6, and IL-12, and the chemotactic cytokine RANTES in patients with chronic sinusitis and polypoid disease. Clinical relevance and relation to allergy. <i>Acta Oto-Laryngologica</i> , 1996 , 116, 604-10	1.6 31
22	Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. <i>International Journal of Cancer</i> , 1996 , 69, 205-11	7.5 103
21	Involvement of BCL-2 oncoprotein in the development of enterochromaffin-like cell gastric carcinoids. <i>American Journal of Surgical Pathology</i> , 1996 , 20, 433-41	6.7 35
20	Calretinin: a novel immunocytochemical marker for mesothelioma. <i>American Journal of Surgical Pathology</i> , 1996 , 20, 1037-46	6.7 390
19	Integrin common chain beta 1 immunoreactivity in hepatocellular carcinoma. <i>Journal of Pathology</i> , 1994 , 172, 363-4	9.4
18	Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma. <i>Cancer</i> , 1994 , 74, 134-41	6.4 21
17	The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. <i>International Journal of Cancer</i> , 1994 , 59, 612-8	7.5 262
16	Pancreatic (acinar) metaplasia of the gastric mucosa. Histology, ultrastructure, immunocytochemistry, and clinicopathologic correlations of 101 cases. <i>American Journal of Surgical Pathology</i> , 1993 , 17, 1134-43	6.7 58

15	Patterns of integrin common chain beta 1 and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size. <i>Journal of Pathology</i> , 1993 , 171, 5-11	9.4	24
14	The outcome from acute subdural and epidural intracranial haematomas in very elderly patients. <i>British Journal of Neurosurgery</i> , 1992 , 6, 227-31	1	66
13	Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. <i>Cancer</i> , 1992 , 70, 2268-77	6.4	78
12	Adult nephroblastoma induced erythrocytosis. Report of a case and review of the literature. <i>Scandinavian Journal of Urology and Nephrology</i> , 1990 , 24, 159-61		7
11	Laryngeal carcinoma showing multidirectional epithelial neuroendocrine and sarcomatous differentiation. <i>Orl</i> , 1990 , 52, 316-26	2	22
10	Long-term follow-up of the surgical treatment of intracranial coenurosis. <i>British Journal of Neurosurgery</i> , 1990 , 4, 39-43	1	23
9	Ultrastructural formation of Langerhans' cell granules in a case of histiocytosis X. <i>Ultrastructural Pathology</i> , 1989 , 13, 89-90	1.3	0
8	Coexpression of cytokeratins and vimentin in normal and diseased thyroid glands. Lack of diagnostic utility of vimentin immunostaining. <i>American Journal of Surgical Pathology</i> , 1989 , 13, 1034-40	6.7	19
7	Coexpression of intermediate filaments in normal and neoplastic human tissues: a reappraisal. <i>Ultrastructural Pathology</i> , 1989 , 13, 501-14	1.3	30
6	Ultrastructural immunolabeling in renal diseases. Past, present and future expectations. <i>Pathology and Immunopathology Research</i> , 1987 , 6, 51-63		18
5	Ultrastructural immunolabeling in the diagnosis of light-chain-related renal disease. <i>Pathology and Immunopathology Research</i> , 1986 , 5, 170-87		24
4	Origin and function of tomato bushy stunt virus-induced inclusion bodies. <i>Journal of Structural Biology</i> , 1986 , 97, 31-38		12
3	Posterior polymorphous dystrophy of the cornea. An ultrastructural study. <i>Graefels Archive for Clinical and Experimental Ophthalmology</i> , 1985 , 223, 265-71	3.8	13
2	Vasoactive intestinal polypeptide-, somatostatin-, and calcitonin-producing adrenal pheochromocytoma associated with the watery diarrhea (WDHH) syndrome. First case report with immunohistochemical findings. <i>Cancer</i> , 1985 , 55, 1099-106	6.4	55
1	Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. <i>Journal of Allergy and Clinical Immunology</i> , 1983 , 72, 294-8	11.5	42